Exelixis reported a 10% year-over-year revenue increase in Q1, driven mainly by strong demand for its drug CABOMETYX. The company improved its operating margin to 41.1% due to cost reductions, supporting robust double-digit growth and strong free cash flow. Despite a 13% rally in its shares, the stock is still considered undervalued with a $57 price target, reflecting 13% upside potential. However, the company's heavy reliance on CABOMETYX for 90% of its revenue poses a risk, emphasizing the need for diversification in its drug pipeline.
Toescoin, a meme coin on the Solana blockchain, is expanding its public website and social media presence to grow its community. The project emphasizes meme culture, humor, and online identity rather than traditional utility, aiming to increase parti...
Patient Square has purchased 210,000 shares of Nektar Pharmaceuticals (NKTR), indicating a significant investment move. This purchase reflects Patient Square's confidence in Nektar's future prospects and potential growth. Investors may view this as a...
A pseudonymous trader named Evaded secured $4.6 million in profits by closing long positions in HYPE, ZEC, and ETH. Immediately after, the trader opened a large short position of 990 bitcoins worth about $74.84 million on Hyperliquid, which had alrea...
Toncoin (TON) fell 11.15% in 24 hours following a 3.35% Bitcoin correction that erased $85 billion from the crypto market cap. Most liquidations were long positions, signaling bearish sentiment. After reaching $2.9 earlier this month, TON’s price is ...
XRP's exchange reserves fell from about 2.74 billion to 2.7 billion XRP in one day, indicating over 35 million XRP were withdrawn from exchanges. This decline suggests increased buying activity by retail and institutional traders, even as XRP's price...
